Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Nektar Therapeutics stock | 16.95

Own Nektar Therapeutics stock in just a few minutes.


Fact checked

Nektar Therapeutics is a biotechnology business based in the US. Nektar Therapeutics shares (NKTR) are listed on the NASDAQ and all prices are listed in US Dollars. Nektar Therapeutics employs 723 staff and has a trailing 12-month revenue of around USD$163.3 million.

How to buy shares in Nektar Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Nektar Therapeutics. Find the stock by name or ticker symbol: NKTR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Nektar Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$16.95, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Nektar Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Nektar Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Nektar Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Nektar Therapeutics's share price has had significant negative movement.

Its last market close was USD$16.95, which is 27.96% down on its pre-crash value of USD$23.53 and 24.36% up on the lowest point reached during the March crash when the shares fell as low as USD$13.63.

If you had bought USD$1,000 worth of Nektar Therapeutics shares at the start of February 2020, those shares would have been worth USD$746.13 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$786.99.

Nektar Therapeutics share price

Use our graph to track the performance of NKTR stocks over time.

Nektar Therapeutics shares at a glance

Information last updated 2020-11-23.
Latest market close USD$16.95
52-week range USD$13.63 - USD$28.49
50-day moving average USD$17.0271
200-day moving average USD$20.2191
Wall St. target price USD$32.15
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.435

Buy Nektar Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nektar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nektar Therapeutics price performance over time

Historical closes compared with the close of $16.95 from 2020-11-16

1 week (2020-11-13) -1.85%
1 month (2020-10-23) -3.36%
3 months (2020-08-21) -11.49%
6 months (2020-05-22) -26.43%
1 year (2019-11-22) -19.55%
2 years (2018-11-21) -54.62%
3 years (2017-11-22) -65.93%
5 years (2015-11-20) 9.43%

Is Nektar Therapeutics under- or over-valued?

Valuing Nektar Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Nektar Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Nektar Therapeutics's PEG ratio

Nektar Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.22. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Nektar Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Nektar Therapeutics financials

Revenue TTM USD$163.3 million
Gross profit TTM USD$93.2 million
Return on assets TTM -13.2%
Return on equity TTM -33.04%
Profit margin -269.05%
Book value $6.527
Market capitalisation USD$2.9 billion

TTM: trailing 12 months

Shorting Nektar Therapeutics shares

There are currently 25.2 million Nektar Therapeutics shares held short by investors – that's known as Nektar Therapeutics's "short interest". This figure is 2.5% down from 25.9 million last month.

There are a few different ways that this level of interest in shorting Nektar Therapeutics shares can be evaluated.

Nektar Therapeutics's "short interest ratio" (SIR)

Nektar Therapeutics's "short interest ratio" (SIR) is the quantity of Nektar Therapeutics shares currently shorted divided by the average quantity of Nektar Therapeutics shares traded daily (recently around 1.1 million). Nektar Therapeutics's SIR currently stands at 23.58. In other words for every 100,000 Nektar Therapeutics shares traded daily on the market, roughly 23580 shares are currently held short.

However Nektar Therapeutics's short interest can also be evaluated against the total number of Nektar Therapeutics shares, or, against the total number of tradable Nektar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nektar Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Nektar Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.2816% of the tradable shares (for every 100,000 tradable Nektar Therapeutics shares, roughly 282 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Nektar Therapeutics.

Find out more about how you can short Nektar Therapeutics stock.

Nektar Therapeutics share dividends

We're not expecting Nektar Therapeutics to pay a dividend over the next 12 months.

Have Nektar Therapeutics's shares ever split?

Nektar Therapeutics's shares were split on a 2:1 basis on 23 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Nektar Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Nektar Therapeutics shares which in turn could have impacted Nektar Therapeutics's share price.

Nektar Therapeutics share price volatility

Over the last 12 months, Nektar Therapeutics's shares have ranged in value from as little as $13.63 up to $28.49. A popular way to gauge a stock's volatility is its "beta".

NKTR.US volatility(beta: 1.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nektar Therapeutics's is 1.885. This would suggest that Nektar Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Nektar Therapeutics overview

Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site